Astrazeneca Ab

Astra Zeneca U.k. Limited

Bryan Glyn Roberts

Stephen Thom

David R Cheshire

Nicholas David Kindon

Andrew Baxter

Thomas McInally

Stephen Brough

Timothy Johnson

Stephen Anthony St-Gallay

Timothy Jon Luker

Paul Andrew Willis

Antonio Mete

Michael Stocks

Garry Pairaudeau

Piotr Antoni Raubo

Nicholas Tomkinson

Barrie Martin

John Steele

Stephen J Brough

Andrew J G Baxter

Matthew Hallam

The present invention relates to isoquinolinone derivatives of formula (I): wherein R, R, R, R, R, Rand Rare as herein defined; processes for their preparation, pharmaceutical compositions containing them and their use in therapy.

Compounds and their uses 707

The present invention relates to isoquinolinone derivatives of formula (I): wherein are as herein defined; processes for their preparation, pharmaceutical compositions containing them and their use in therapy.

Isoquinolinone derivatives

The invention provides N-pyrazinyl-phenyl-sulphonamides of formula (I) for use in the treatment of chemokine mediated diseases. Particularly inflammatory diseases, such as asthma. 

N-pyrazinyl-phenylsulphonamides and their use in the treatment of chemokine mediated diseases

The invention provides N-pyrazinyl-thienylsulphonamides of formula (I) for use in the treatment of chemokine mediated diseases. Particularly inflammatory diseases, such as asthma 

Compounds

The invention provides compounds of general formulawherein R, m, Q, T, n, R, R, V, W, X and Rare as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.

The invention provides piperidine compounds of general formula (I) in which A, B, X, Y, Z, R, R and R are as defined in the specification, their use as medicaments, compositions containing them and processes for their for their preparation.

P2X7 receptor antagonists for use in the treatment of inflammatory, immune or cardiovascular disease

Piperazine derivatives as modulators of chemokine receptor activity

The invention provides compounds of general formula (I) wherein: R represents optionally substituted, C -C alkyl or optionally substituted 3- to 10-membered saturated or unsaturated ring system comprising up to two ring carbon atoms that form carbonyl groups and comprising up to 4 ring heteroatoms independently selected from nitrogen, oxygen and sulfur; m is 0-1; Q represents OCH , C -C alkylene or C -C alkenylene; T represents C(O)NH, or when m is 0, T may additionally represent a bond or NH, or when m is 1 and Q represents C -C alkylene, T may additionally represent NH; n is 1-4; each R and R independently represents H or C -C alkyl; V represents N, and W represents N or CH; X represents O, C(O), CH(OH), SO , NH or N(C -C alkyl), provided that when W represents N, then X represents either C(O) or SO and when W represents CH, then X is other than SO ; R represents optionally substituted phenyl; R and R each independently represent H, C -C alkyl or hydroxyC -C alkyl, or R and R together with the nitrogen atom to which they are attached form a 4- to 7-membered saturated heterocyclic ring; R and R each independently represent H or C -C alkyl; and R represents OH or &mdash;NR R ; processes for their preparation, pharmaceutical compositions containing them and their use in therapy.

Growing community of inventors

Loughborough, United Kingdom

Bryan Glyn Roberts